Therapy News and Research

RSS

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

9 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

Laborie acquires UroMed's pelvic muscle rehabilitation business

Laborie Medical Technologies, Inc., a portfolio company of Audax Group, announced it has completed the acquisition of UroMed Technology, Inc.'s pelvic muscle rehabilitation business.

9 Oct 2013

ReAttach therapy can be effective treatment for people with autism

"ReAttach" is a new intervention, based on "attachment". Practical research has pointed out that the "ReAttach therapy" can be of great importance for people with autism. This is concluded from the continuous practical research of Paula Bartholomeus into the advantages that can be reached for people with Asperger's syndrome, PDD-NOS, autism spectrum disorder, or with a mental disability and autism, using the ReAttach therapy.

9 Oct 2013

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).

9 Oct 2013

MRFBC launches clinical trial to assess impact of bevacizumab and vemurafenib in melanoma patients

The Melanoma Research Foundation Breakthrough Consortium has launched a new clinical trial to assess the impact of concomitant administration of bevacizumab (Avastin) with vemurafenib (Zelboraf) in patients with BRAFV600 mutation positive metastatic melanoma.

8 Oct 2013

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.

8 Oct 2013

Metastatic site impacts survival in targeted RCC treatment

Bone and liver metastases may have the heaviest impact on the survival of patients receiving targeted therapy for metastatic renal cell carcinoma, suggest data from the International Metastatic Renal Cell Carcinoma Database Consortium.

8 Oct 2013

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

Professor Richard Pleass has won the Prix de l’Innovation 2013, also known as the Universal Biotech Innovation Prize 2013.

8 Oct 2013

Personalised therapy can reduce risk of cardiac disease among diabetes patients

600,000 to 800,000 Austrians suffer from diabetes mellitus. Thanks to the biomarker known as NT-proBNP (a hormone specific to the heart), the sub-group of people who are at increased risk of cardiovascular disease can be determined even though their hearts appear to be healthy.

8 Oct 2013

In South Africa, rapid progress in reducing under-five mortality

Over the past decade, South Africa has made a dramatic reversal in child survival-mainly because of improvements in HIV/AIDS care, reports a study in AIDS, official journal of the International AIDS Society. AIDS is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

8 Oct 2013

Two researchers receive $2.5M grant to continue their research on cancer cell growth

A pair of researchers at Rutgers Cancer Institute of New Jersey has been awarded nearly $2.5 million dollars to further study in their respective laboratories.

8 Oct 2013

Study: Effect of medication treatments on patients with alcoholism and anxiety

Domenic Ciraulo, MD, chair of psychiatry at Boston University School of Medicine (BUSM) and David H. Barlow, PhD, professor of psychology at Boston University (BU), have collaborated to study the effect of behavioral and medication treatments on patients with alcoholism and anxiety.

8 Oct 2013

Research: Triathletes feel less pain than casual exercisers

Triathletes participate in a grueling endurance sport, swimming, bicycling, and running long distances without rest. In training and competitions, they regularly push their bodies beyond the limits most of us can endure. But while there is no doubt that triathletes are tough, very little is known about what gives them their exceptional abilities.

8 Oct 2013

PET scan shows promise in predicting patients with inoperable lung cancer

Advanced imaging with Positron Emission Tomography (PET) scan shows great promise in predicting which patients with inoperable lung cancer have more aggressive tumors and need additional treatment following standard chemotherapy/radiation therapy, according to new research recently published online in the Journal of Clinical Oncology.

8 Oct 2013

Parasites in patients who relapse after leishmaniasis treatment may have greater infectivity

Relapses after treatment for Leishmania infection may be due to a greater infectivity of the parasite rather than drug resistance, as has been previously thought, according to a study published in mBio-, the online open-access journal of the American Society for Microbiology.

8 Oct 2013

Noncardiac surgery after recent coronary stent linked with increased risk of adverse cardiac events

Emergency surgery and advanced cardiac disease are risk factors for major adverse cardiac events (MACE) after noncardiac surgery in patients with recent coronary stent implantation, according to a study published by JAMA.

8 Oct 2013

LSUHSC receives $2.76M grant to study how HIV affect oral bacterial communities

Dr. Paul Fidel, the Carl Baldridge Professor and Associate Dean for Research at LSU Health Sciences Center New Orleans' School of Dentistry, is the lead principal investigator of a $2.76 million grant from the National Institute of Dental and Craniofacial Research over five years to study how HIV and antiretroviral therapy may change communities of bacteria in the mouth and what effects those changes may have on oral infections in HIV disease.

8 Oct 2013

Scientists devised technique to make antibody-drug conjugates, basis of new therapies

Chemists at The Scripps Research Institute (TSRI) have devised a new technique for connecting drug molecules to antibodies to make advanced therapies.

8 Oct 2013

Advantages of on-site analytical laboratories outlined in new white paper from PCI

PCI, a global supplier of pharmaceutical commercial packaging solutions and clinical trials services, announces the availability of a white paper detailing the advantages of having on-site analytical laboratories in order to meet the needs of the pharmaceutical industry.

From Packaging Coordinators Inc. (PCI) 7 Oct 2013

Therapy News and Research

Bayer HealthCare receives FDA approval for Adempas tablets

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Laborie acquires UroMed's pelvic muscle rehabilitation business

ReAttach therapy can be effective treatment for people with autism

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

MRFBC launches clinical trial to assess impact of bevacizumab and vemurafenib in melanoma patients

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Metastatic site impacts survival in targeted RCC treatment

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

Personalised therapy can reduce risk of cardiac disease among diabetes patients

In South Africa, rapid progress in reducing under-five mortality

Two researchers receive $2.5M grant to continue their research on cancer cell growth

Study: Effect of medication treatments on patients with alcoholism and anxiety

Research: Triathletes feel less pain than casual exercisers

PET scan shows promise in predicting patients with inoperable lung cancer

Parasites in patients who relapse after leishmaniasis treatment may have greater infectivity

Noncardiac surgery after recent coronary stent linked with increased risk of adverse cardiac events

LSUHSC receives $2.76M grant to study how HIV affect oral bacterial communities

Scientists devised technique to make antibody-drug conjugates, basis of new therapies

Advantages of on-site analytical laboratories outlined in new white paper from PCI

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News